According to the Union Health Ministry, an uptick in covid cases has been observed in various states in India including Karnataka, Kerala, Maharashtra, and Jharkhand. With the reports of JN.1, a new Covid variant, 2,669 active cases were reported in 24 hours on Thursday.
Listed below are the stocks that fall under the diagnostics centre segment which may benefit due to an increase in COVID cases:
Dr. Lal Pathlabs Ltd
With a market capitalization of 21,952 crores, the shares of Dr Lal Pathlabs Ltd started Friday’s trading session on a higher note at Rs. 2,600 compared to its previous close of Rs. 2,590.18. The share hit a high of Rs. 2,647, gaining around 2 percent and currently trading at Rs. 2,638.45 apiece.
Coming onto the company’s financial statements, the revenue increased by 11 percent from Rs. 541 crores during the June quarter to Rs. 601 crores in the September quarter. In addition, the net profit zoomed by 32 percent from Rs. 84 crores to Rs. 111 crores during the same timeframe.
The company gets revenue from across India, primarily from Delhi which contributes 32 percent of the revenue, they get revenue of 14 percent from the eastern part of the country, 16 percent from the west, 6 percent from the southern part and 30 percent from the rest of north India.
As of FY23, the company has 277 clinical labs, 5102 Patient Service Centers (PSC) and 10,938 Pick-up Points(PUPs). This extensive network enables the company to provide diagnostic services and a wide range of tests to a large number of patients across the country.
Vijaya Diagnostic Centre Ltd
With a market capitalization of 6,613 crores, the shares of Vijaya Diagnostic Centre Ltd started Friday’s trading session on a higher note at Rs. 650 compared to its previous close of Rs. 647.25. The share hit a high of Rs. 643, gaining around 1 percent and currently at Rs. 645 apiece.
Coming onto the company’s financial statements, the revenue increased by 15 percent from Rs. 121 crores during the June quarter to Rs. 139 crores in the September quarter. In addition, the net profit zoomed by 31 percent from Rs. 26 crores to Rs.34 crores during the same timeframe.
Vijaya Diagnostic Centre, a leading blood test laboratory in India, operates more than 100 diagnostic centres in more than 17 cities across the country. The company gets revenue from multiple sources, primarily from radiology which contributes 36 percent of revenue and the remaining 64 percent of revenue comes from pathology.
Metropolis Healthcare Ltd
With a market capitalisation of 8,876 crores, the shares of Metropolis Healthcare Ltd started Friday’s trading session on a higher note at Rs. 1,710 compared to its previous close of Rs. 1,709. The share hit a high of Rs. 1,754, gaining around 3 percent, also recorded as the company’s fresh 52-week high and currently trading at Rs. 1,744 apiece.
Coming onto the company’s financial statements, the revenue increased by 9 percent from Rs. 773 crores during the June quarter to Rs 844 crores in the September quarter. In addition, the net profit zoomed by 23 percent from Rs. 102 crores to Rs.125 crores during the same timeframe.
As of H1FY24, the company has 165 labs, 285 owned Patient Service Centers, 2,774 third-party Patient Service Centers and 25 ARC.
The company gets revenue from across India, primarily 51 percent of the revenue comes from the western part of India, 30 percent from the southern part, 8 percent from north India, 5 percent from the eastern part and the remaining 6 percent of revenue is contributed from international regions.
Written By Vaibhav Patil
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
